deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00194792

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study

Sponsor: National Cancer Institute (NCI)

Conditions Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer Progesterone Receptor-positive Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer
Interventions capecitabine exemestane laboratory biomarker analysis methotrexate paclitaxel radiation therapy therapeutic conventional surgery triptorelin pamoate vinorelbine tartrate
Updated 8 times since 2017 Last updated: Jun 9, 2017 Started: Aug 31, 2005 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Listed as NCT00194792, this PHASE2 trial focuses on Estrogen Receptor-positive Breast Cancer and HER2-negative Breast Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotTerminated~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Present [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2017 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Washington
Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations